2-pyrrolidinone derivatives substituted at position 4 for...

Details 2-pyrrolidinone derivatives substituted at position 4 for... 2-pyrrolidinone derivatives substituted at position 4 for...

2006-01-10

2006-01-10

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S408000, C514S409000

Reexamination Certificate

active

06984659

ABSTRACT:
2-pyrrolidinone derivatives which have in position 4 at least one substituent are described herein. Methods of treating polygltamine disorders such as Huntington's disease, dentorubropallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and spinocerebellar ataxias with 2-pyrrolidinone derivatives are also descibed.

REFERENCES:
patent: 5068413 (1991-11-01), Steiner et al.
patent: 5319135 (1994-06-01), Jennings et al.
patent: 6054482 (2000-04-01), Augart et al.
patent: 0 414 263 (1991-02-01), None
patent: 0 446 570 (1991-09-01), None
patent: 1 289 365 (2003-12-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
Kearney et al. The effect of cyclodextrins on the rate of intramolecular lactamization of gabapentin in aqueous solution, 1992, International Journal of Pharmaceutics, vol. 78, pp. 25-34.
Enders, A. et al., “Pharmacology of a new group of centrally stimulating drugs”, Arzneimittel-Forschung, 1960, pp. 243-250.
Nakamura, J. et al., “Comparative Studies on the Anticonvulsant Activity of Lipophilic Derivatives of y-Aminobutyric Acid and 2-Pyrrolidinone in Mice”, J. Pharmacobio-Dyn., 1991, pp. 1-8, Vo. 14.
Reedy, P.A., et al., “3-3-Dialkyl- and 3-Alkyl-3-Benzyl-Substituted 2-Pyrrolidinones: A New Class of Anticonvulsant Agents”, J. Med. Chem., 1996, pp. 1898-1906, vol. 39.
Perez De La Mora, M., et al., “Anticonvulsant effect of 5-ethyl, 5-phenyl, 2-pyrrolidione and its possible relationship to y-aminobutyric acid-dependent inhibitory mechanisms”, Biochemical Pharmacology, 1973, pp. 2635-2639, vol. 22.
Waldmeier, P.C., et al., “Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum”, Naunyn Schmiedeberg's Arch Pharmacol, 1996, pp. 164-172, vol. 354.
Sarbbani: Sahay Guha Sircab, “The Preparation of the Substituted Butyrolaccams”, J. Ind. Chem., 1928, p. 552, vol. 5.
Siesjo, B.K., et al., “Calcium, Excitotoxins, and Neuronal Death in the Brain”, Annals NY Acad. Sci, 1989, pp. 234-251, vol. 568.
Liu, H.T. et al., “NMDA-receptor regulation of substance P release from primary afferent nociceptors”, Nature, 1997, pp. 721-724, vol. 386.
Bryson, H.M. et al., “Riluzole: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis”, Drug Evaluation, 1996, pp. 549-563, vol. 52.
La Spada AR, Taylor JP (2003) Polyglutamine placed into context. Neuron 38:681-684.
Bonini NM, Fortini ME (2003) Neurosci Human Neurodegenerative Disease Modeling Using Drosophila. Annu Rev 26, Epub ahead of print.

Affiliated with

Also associated with

Rating

2-pyrrolidinone derivatives substituted at position 4 for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-pyrrolidinone derivatives substituted at position 4 for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyrrolidinone derivatives substituted at position 4 for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3574870